Literature DB >> 3037124

Bilateral testicular germ cell tumors: a report of 20 cases.

K Scheiber, D Ackermann, U E Studer.   

Abstract

Of 412 patients with unilateral testicular cancer 20 (4.3 per cent) suffered a second primary germ cell tumor: 1 had a simultaneous bilateral tumor and in the remaining 19 the second tumor was diagnosed after an interval of 2 months to 32 years. Patients with clinical stages III and IV disease were found only in the group with a second tumor. In 5 patients known risk factors for the development of testicular tumors were found and in 2 prior testicular biopsies showed carcinoma in situ. Effective chemotherapy was used more often in the treatment of the second primary tumor. Of the 20 patients 18 (90 per cent) are free of disease after a mean observation of 5.7 years. A long followup of testicular cancer patients with sonographic evaluation of the remaining testis as well as periodic self-examination by the patient is required.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3037124     DOI: 10.1016/s0022-5347(17)42995-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

Review 1.  Bilateral testicular germ cell tumors.

Authors:  Haşmet Sarıcı; Onur Telli; Muzaffer Eroğlu
Journal:  Turk J Urol       Date:  2013-12

2.  Inheritance and testicular cancer.

Authors:  P W Nicholson; S J Harland
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

3.  Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy.

Authors:  Ch Theodore; M J Terrier-Lacombe; A Laplanche; G Benoit; K Fizazi; O Stamerra; P Wibault
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

4.  Sequential bilateral testicular tumours presenting with intervals of 20 years and more.

Authors:  Klaus-Peter Dieckmann; Petra Anheuser; Florentine Sattler; Tobias Von Kügelgen; Cord Matthies; Christian Ruf
Journal:  BMC Urol       Date:  2013-12-09       Impact factor: 2.264

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.